The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Primary age-related tauopathy (PART): a common pathology associated with human aging
Open accessAbstract
We recommend a new term, "primary age-related tauopathy" (PART), to describe a pathology that is commonly observed in the brains of aged individuals. Many autopsy studies have reported brains with neurofibrillary tangles (NFTs) that are indistinguishable from those of Alzheimer's disease (AD), in the absence of amyloid (Aβ) plaques. For these "NFT+/Aβ-" brains, for which formal criteria for AD neuropathologic changes are not met, the NFTs are mostly restricted to structures in the medial temporal lobe, basal forebrain, brainstem, and olfactory areas (bulb and cortex). Symptoms in persons with PART usually range from normal to amnestic cognitive changes, with only a minority exhibiting profound impairment. Because cognitive impairment is often mild, existing clinicopathologic designations, such as "tangle-only dementia" and "tangle-predominant senile dementia", are imprecise and not appropriate for most subjects. PART is almost universally detectable at autopsy among elderly individuals, yet this pathological process cannot be specifically identified pre-mortem at the present time. Improved biomarkers and tau imaging may enable diagnosis of PART in clinical settings in the future. Indeed, recent studies have identified a common biomarker profile consisting of temporal lobe atrophy and tauopathy without evidence of Aβ accumulation. For both researchers and clinicians, a revised nomenclature will raise awareness of this extremely common pathologic change while providing a conceptual foundation for future studies. Prior reports that have elucidated features of the pathologic entity we refer to as PART are discussed, and working neuropathological diagnostic criteria are proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Perivascular, subpial, and periventricular p-tau immunoreactive NFTs and astrocytic tangles in the neocortex have been reported to be characteristic of both primary age-related tauopathy (PART) [35] and age-related tau astrogliopathy (ARTAG) [36].”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Primary age-related tauopathy (PART) and aging-related tau astrogliopathy (ARTAG) are independent tau pathologies commonly observed in patients over 80 years of age, and PART may account for a proportion of the misdiagnosed clinical AD cases in the elderly [130, 141, 142].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [142]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lesions are found in the hippocampus and adjacent regions similar to those observed in Braak I-IV, but PART is distinct from AD in that it lacks amyloid plaques, and it has distinct morbidity and age range [130, 142].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [142]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PART refers to neuronal tau pathology and ARTAG is characterized by astrocytic tau pathology, although they are not mutually exclusive, and appear to be more a manifestation of age than a subtype of neurodegenerative disease.”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many studies, from the histopathology of Braak and Braak4 to longitudinal studies of Tau positron emission tomography imaging27,28, demonstrate that MTG is a transition zone between aging-related or preclinical AD-related medial temporal lobe pTau and more advanced stages of AD, where neocortical pTau extends across the brain and is strongly correlated with dementia4,29–31.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [29]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It should be noted that tau aggregation in the brain is associated with older age and is generally uncommon in healthy young adults (Braak et al., 2011; Crary et al., 2014).”
From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Crary et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE and PART are common neuropathologies, indicating the importance of addressing potential relationships between AD-Mimics, and LATE and PART pathology in future research (20,22).”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“AD-Mimics and definite PART are both defined as having no neuritic plaques, and like the AD-Mimics in this study, PART participants are generally older and experience less severe cognitive dysfunction (22,23).”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“The compact NFTs observed are morphologically most like those seen in primary age-related tauopathy (PART) [4], Alzheimer’s disease (AD) [22], and chronic traumatic encephalopathy (CTE) [13, 14], but the topographical distribution and immunostaining characteristics differ from these more common tauopathies in several respects.”
From Tuberous sclerosis complex is associated with a novel human tauopathy (2023) · cites this paper as [4]
In the citing paper
“APOE4 significantly aggravated tau-mediated neurodegeneration in a tauopathy mouse model and induced tau aggregates in brain, while genetic ablation of APOE attenuated tau-induced neurodegeneration [469, 470].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [470]
In the citing paper
“In AD and PART, the tau aggregates are a mixture of three-repeat and four-repeat tau isoforms, whereas four-repeat sequences dominate in PSP and CBD and three-repeat sequences predominate in Pick disease14,18,19,21.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [14]
In the citing paper
“More recently, Crary et al. coined the term “primary age-related tauopathy” (PART) after observing that the postmortem brains of many elderly individuals harbor NFTs indistinguishable from those of AD but in the absence of Aβ plaques or cognitive decline [44].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [44]
In the citing paper
“The panel did not ultimately accept all of the a priori criteria for CTE; they did not include pathology known to be associated with aging (i.e.primary age-related tauopathy [PART] [16] and aging-related tau astrogliopathy [ARTAG] [17]).”
From Mild Chronic Traumatic Encephalopathy Neuropathology in People With No Known Participation in Contact Sports or History of Repetitive Neurotrauma (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 3×
“the current guidelines for AD [64, 102], mild Aβ plaques”
BackgroundInfluentialSelf-citationConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,002
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160836 · Cited by 244
Imaging biomarkers in neurodegeneration: current and future practices
Young, P. N. E., Estarellas, M., Coomans, E. M., Srikrishna, M., Beaumont, H., Maaß, A., Venkataraman, A. V., Lissaman, R., Jiménez, D., Betts, M. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00612-7 · Cited by 244
Ehrenberg, A. J., Nguy, A. K., Theofilas, P., Dunlop, S. R., Suemoto, C. K., Alho, A. T. D. L., Leite, R. P., Rodriguez, R. D., Mejia, M. B., Rüb, U., et al. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12387 · Cited by 243
Self-citationFunctional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease
Franzmeier, N., Rubinski, A., Neitzel, J., Kim, Y., Damm, A., Na, D. L., Kim, H. J., Lyoo, C. H., Cho, H., Finsterwalder, S., et al. (2019) · Brain · doi:10.1093/brain/awz026 · Cited by 243
Neuropathological criteria of anti-IgLON5-related tauopathy
Gelpí, E., Höftberger, R., Graus, F., Ling, H., Holton, J. L., Dawson, T., Popović, M., Oblak, J. P., Högl, B., Schmutzhard, E., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1591-8 · Cited by 242
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum
Jones, D. T., Graff‐Radford, J., Lowe, V. J., Wiste, H. J., Gunter, J. L., Senjem, M. L., Botha, H., Kantarci, K., Boeve, B. F., Knopman, D. S., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.09.018 · Cited by 239
Self-citationLashley, T., Rohrer, J. D., Mead, S., & Révész, T. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12250 · Cited by 234
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
Lewis, J. M., & Dickson, D. W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1507-z · Cited by 229
Self-citationCellular and pathological heterogeneity of primary tauopathies
Chung, D. C., Roemer, S. F., Petrucelli, L., & Dickson, D. W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00476-x · Cited by 232
Self-citation(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00025-0 · Cited by 225
Besser, L. M., Kukull, W. A., Teylan, M. A., Bigio, E. H., Cairns, N. J., Kofler, J. K., Montine, T. J., Schneider, J. A., & Nelson, P. T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly049 · Cited by 224
Self-citationGoedert, M., & Spillantini, M. G. (2017) · Molecular Brain · doi:10.1186/s13041-017-0298-7 · Cited by 213
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L. G., Murray, M. E., Verberk, I. M. W., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 225
Self-citationMorris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Tauopathies as clinicopathological entities
Irwin, D. J. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.020 · Cited by 212
Deep ensemble learning for Alzheimer's disease classification
An, N., Ding, H., Yang, J., Au, R., & Ang, T. F. A. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2020.103411 · Cited by 212
Alzheimer’s pathology targets distinct memory networks in the ageing brain
Maaß, A., Berron, D., Harrison, T. M., Adams, J. N., Joie, R. L., Baker, S. L., Mellinger, T. J., Bell, R. K., Swinnerton, K. N., Inglis, B. A., et al. (2019) · Brain · doi:10.1093/brain/awz154 · Cited by 209
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Pereira, J. B., Janelidze, S., Ossenkoppele, R., Kvartsberg, H., Brinkmalm, A., Mattsson, N., Stomrud, E., Smith, R. A., Zetterberg, H., Blennow, K., et al. (2020) · Brain · doi:10.1093/brain/awaa395 · Cited by 208
Tau-positron emission tomography correlates with neuropathology findings.
Lowe, V. J., Lundt, E. S., Albertson, S. M., Min, H., Fang, P., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Kantarci, K., Boeve, B., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.079 · Cited by 203
Self-citationThe development and convergence of co-pathologies in Alzheimer’s disease
Robinson, J. L., Richardson, H., Xie, S. X., Suh, E., Van Deerlin, V. M., Alfaro, B., Loh, N., Porras-Paniagua, M., Nirschl, J. J., Wolk, D., et al. (2021) · Brain · doi:10.1093/brain/awaa438 · Cited by 203
Self-citationAltered Proteins in the Aging Brain
Elobeid, A., Libard, S., Leino, M., Popova, S. N., & Alafuzoff, I. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw002 · Cited by 202
Self-citationJack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200
Self-citationSanchez, J. S., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Jiang, S., Schultz, A. P., Properzi, M. J., Katz, S. R., Beiser, A., Satizabal, C. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0655 · Cited by 200
Regional Aβ-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading
Lee, W. J., Brown, J. A., Kim, H. R., Joie, R. L., Cho, H., Lyoo, C. H., Rabinovici, G. D., Seong, J., & Seeley, W. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.034 · Cited by 198
Self-citationNeuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01083-5 · Cited by 196
The development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 193
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Lowe, V. J., Graff‐Radford, J., Roberts, R. O., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25071 · Cited by 189
Self-citationCryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607
Shi, Y., Murzin, A. G., Falcon, B., Epstein, A., Machin, J., Tempest, P. A., Newell, K. L., Vidal, R., Garringer, H. J., Sahara, N., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02294-3 · Cited by 189
Minoshima, S., Cross, D. J., Thientunyakit, T., Foster, N. L., & Drzezga, A. E. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263194 · Cited by 185
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Self-citationAlzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Lacampagne, A., Liu, X., Reiken, S., Bussiere, R., Meli, A. C., Lauritzen, I., Teich, A. F., Zalk, R., Saint, N., Arancio, O., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1733-7 · Cited by 181
Self-citationNelson, P. T., Brayne, C., Flanagan, M. E., Abner, E. L., Agrawal, S., Attems, J., Castellani, R. J., Corrada, M. M., Cykowski, M. D., Di, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02444-1 · Cited by 187
Self-citationGordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180
Self-citationIn Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
Sepulcre, J., Schultz, A. P., Sabuncu, M. R., Gómez‐Isla, T., Chhatwal, J. P., Becker, A., Sperling, R. A., & Johnson, K. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0639-16.2016 · Cited by 182
Vilas, D., Iranzo, Á., TOLOSA, E. S., Aldecoa, I., Berenguer, J., Vilaseca, I., Martí, C. D., Serradell, M., Lomeña, F., Alós, L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00080-6 · Cited by 179
Concussion in chronic traumatic encephalopathy
Stein, T. D., Alvarez, V. E., & McKee, A. C. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0522-z · Cited by 177
Self-citationQuantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers
Smailovic, U., Koenig, T., Kåreholt, I., Andersson, T., Kramberger, M. G., Winblad, B., & Jelic, V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.005 · Cited by 177
Buckley, R. F., Hanseeuw, B., Schultz, A. P., Vannini, P., Aghjayan, S. L., Properzi, M. J., Jackson, J. D., Mormino, E. C., Rentz, D. M., Sperling, R. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2216 · Cited by 173
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.
Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., Dickson, D. W., Hof, P. R., Hyman, B. T., Jack, C. R., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1407-2 · Cited by 171
Self-citationJosephs, K. A., Murray, M. E., Tosakulwong, N., Whitwell, J. L., Knopman, D. S., Machulda, M. M., Weigand, S. D., Boeve, B. F., Kantarci, K., Petrucelli, L., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1681-2 · Cited by 169
Self-citationLattanzio, F., Abu‐Rumeileh, S., Franceschini, A., Kai, H., Amore, G., Poggiolini, I., Rossi, M., Baiardi, S., McGuire, L. I., Ladogana, A., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1683-0 · Cited by 168
Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 168
Disentangling Heterogeneity in Alzheimer’s Disease and Related Dementias Using Data-Driven Methods
Habes, M., Grothe, M. J., Tunc, B., McMillan, C., Wolk, D. A., & Davatzikos, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.016 · Cited by 167
Koper, M. J., Schoor, E. V., Ospitalieri, S., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Tousseyn, T., Balusu, S., Strooper, B. D., & Thal, D. R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02103-y · Cited by 167
Self-citationAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study
Robinson, J. L., Corrada, M. M., Kovács, G. G., Dominique, M. A., Caswell, C., Xie, S. X., Lee, V. M. ‐., Kawas, C. H., & Trojanowski, J. Q. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1872-5 · Cited by 166
Self-citationMatěj, R., Tesař, A., & Rusina, R. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.005 · Cited by 164
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Henderson, M. X., Sengupta, M., Trojanowski, J. Q., & Lee, V. M. ‐. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0836-x · Cited by 164
Self-citationThe basis of cellular and regional vulnerability in Alzheimer’s disease
Mrdjen, D., Fox, E. J., Bukhari, S. A., Montine, K. S., Bendall, S. C., & Montine, T. J. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02054-4 · Cited by 162
Self-citationThal, D. R., Beach, T. G., Zanette, M., Heurling, K., Chakrabarty, A., Ismail, A., Smith, A. P. L., & Buckley, C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.018 · Cited by 159
Self-citationEpigenetics of dementia: understanding the disease as a transformation rather than a state
Maloney, B., & Lahiri, D. K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00065-x · Cited by 159
Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies
Hepp, D. H., Vergoossen, D. L. E., Huisman, E., Lemstra, A. W., Bank, N. B., Berendse, H. W., Rozemüller, A. J. M., Foncke, E. M. J., & van de Berg, W. D. J. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw070 · Cited by 159
“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)
Nelson, P. T., Trojanowski, J. Q., Abner, E. L., Al-Janabi, O. M., Jicha, G. A., Schmitt, F. A., Smith, C. D., Fardo, D. W., Wang, W.-X., Kryscio, R. J., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw033 · Cited by 158
Self-citationRetiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies
Forrest, S. L., Kril, J. J., Stevens, C. H., Kwok, J. B., Hallupp, M., Kim, W. S., Huang, Y. M., McGinley, C. V., Werka, H., Kiernan, M. C., et al. (2017) · Brain · doi:10.1093/brain/awx328 · Cited by 156
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02449-2 · Cited by 155
Self-citationChallenges of multimorbidity of the aging brain: a critical update
Jellinger, K. A., & Attems, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1288-x · Cited by 154
Self-citationα‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies
Bongianni, M., Ladogana, A., Capaldi, S., Klotz, S., Baiardi, S., Cagnin, A., Perra, D., Fiorini, M., Poleggi, A., Legname, G., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50897 · Cited by 153
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
Smailović, U., & Jelić, V. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00169-0 · Cited by 152
Genetics of FTLD : overview and what else we can expect from genetic studies
Pottier, C., Ravenscroft, T. A., Sanchez‐Contreras, M., & Rademakers, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13622 · Cited by 148
Pupillary Responses as a Biomarker of Early Risk for Alzheimer’s Disease
Granholm, E. L., Panizzon, M. S., Elman, J. A., Jak, A. J., Hauger, R. L., Bondi, M. W., Lyons, M. J., Franz, C. E., & Kremen, W. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161078 · Cited by 147
Dahl, M. J., Mather, M., Werkle‐Bergner, M., Kennedy, B. L., Guzman, S. J., Hurth, K. M., Miller, C. A., Qiao, Y., Shi, Y., Chui, H. C., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.11.006 · Cited by 149
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Henjum, K., Almdahl, I. S., Årskog, V., Minthon, L., Hansson, O., Fladby, T., & Nilsson, L. N. G. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0182-1 · Cited by 145
Davidson, Y. S., Robinson, A., Prasher, V. P., & Mann, D. M. A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0559-4 · Cited by 146
Marks, S. M., Lockhart, S. N., Baker, S. L., & Jagust, W. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3769-16.2017 · Cited by 144
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 144
Self-citationAssociation of APOE with tau-tangle pathology with and without β-amyloid
Farfel, J. M., Yu, L., Jager, P. L. D., Schneider, J. A., & Bennett, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.011 · Cited by 142
Self-citationWhat causes neurodegenerative disease?
Armstrong, R. A. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.96707 · Cited by 143
Mechanobiology of the brain in ageing and Alzheimer's disease
Hall, C. M., Moeendarbary, E., & Sheridan, G. K. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14766 · Cited by 140
Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140
The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
Nelson, P. T., Abner, E. L., Patel, E., Anderson, S., Wilcock, D. M., Kryscio, R. J., Eldik, L. J. V., Jicha, G. A., Gal, Z. T., Nelson, R. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx099 · Cited by 141
Self-citationAPOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139
Self-citationTau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow, E., Mandelkow, E., Miller, D. S., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.018 · Cited by 139
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
Kovács, G. G., Xie, S. X., Robinson, J. L., Lee, E. B., Smith, D. H., Schuck, T., Lee, V. M. ‐., & Trojanowski, J. Q. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0552-y · Cited by 137
Self-citationAlzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Self-citationNeuropathological and transcriptomic characteristics of the aged brain
Miller, J. A., Guillozet-Bongaarts, A., Gibbons, L. E., Postupna, N., Renz, A., Beller, A. E., Sunkin, S. M., Ng, L., Rose, S. E., Smith, K. A., et al. (2017) · eLife · doi:10.7554/elife.31126 · Cited by 134
Self-citationTauopathy: A common mechanism for neurodegeneration and brain aging
Saha, P., & Sen, N. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.01.007 · Cited by 134
Strikwerda‐Brown, C., Hobbs, D. A., Gonneaud, J., St‐Onge, F., Binette, A. P., Ozlen, H., Provost, K., Soucy, J., Buckley, R. F., Benzinger, T. L. S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2379 · Cited by 134
Self-citationAdamowicz, D. H., Roy, S., Salmon, D. P., Galasko, D. R., Hansen, L. A., Masliah, E., & Gage, F. H. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3047-16.2016 · Cited by 133
Self-citationArtificial intelligence in neuropathology: deep learning-based assessment of tauopathy
Signaevsky, M., Prastawa, M. W., Farrell, K. W., Tabish, N., Baldwin, E., Han, N., Iida, M. A., Koll, J., Bryce, C., Purohit, D. P., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0202-4 · Cited by 133
Self-citationKovacs, G. G., Robinson, J. L., Xie, S. X., Lee, E. B., Grossman, M., Wolk, D. A., Irwin, D. J., Weintraub, D., Kim, C. F., Schuck, T., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx007 · Cited by 132
Self-citationHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo
Vergara, C., Houben, S., Suain, V., Yilmaz, Z., Decker, R. D., Dries, V. V., Boom, A., Mansour, S., Leroy, K., Ando, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1953-5 · Cited by 131
Rhinn, H., & Abeliovich, A. (2017) · Cell Systems · doi:10.1016/j.cels.2017.02.009 · Cited by 130
Grothe, M. J., Heinsen, H., Amaro, E., Grinberg, L. T., & Teipel, S. J. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv062 · Cited by 130
Self-citationThe basis of clinicopathological heterogeneity in TDP-43 proteinopathy
Kawakami, I., Arai, T., & Hasegawa, M. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02077-x · Cited by 130
Jack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129
Self-citation(2022) · doi:10.1038/s41467-022-34129-4 · Cited by 128
Self-citationParkinson disease and incidental Lewy body disease
Iacono, D., Geraci-Erck, M., Rabin, M., Adler, C. H., Serrano, G. E., Beach, T. G., & Kurlan, R. (2015) · Neurology · doi:10.1212/wnl.0000000000002102 · Cited by 128
Self-citationDong, Y., Yu, H., Li, X., Bian, K., Zheng, Y., Dai, M., Feng, X., Sun, Y., He, Y. T., Yu, B., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02567-y · Cited by 127
Calderón‐Garcidueñas, A. L., & Duyckaerts, C. J. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00023-7 · Cited by 126
CSF Cytokines in Aging, Multiple Sclerosis, and Dementia
Hu, W. T., Howell, J. C., Ozturk, T. T., Gangishetti, U., Kollhoff, A. L., Hatcher-Martin, J. M., Anderson, A. M. L., & Tyor, W. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00480 · Cited by 126
Small-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomović, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 124
Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases
Li, D., & Liu, C. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00603-7 · Cited by 124
Prevalence of preclinical Alzheimer disease
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Wærn, M., Höglund, K., Andréasson, U., Wetterberg, H., Börjesson‐Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 123
Staging of Alzheimer’s disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S. G., & Rosa‐Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 123
Metadata
- Authors
- Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Gearing, M., Grinberg, L. T., Hof, P. R., Hyman, B. T., Jellinger, K., Jicha, G. A., Kovacs, G. G., Knopman, D. S., Kofler, J., Kukull, W. A., Mackenzie, I. R., Masliah, E., McKee, A., Montine, T. J., Murray, M. E., Neltner, J. H., Santa-Maria, I., Seeley, W. W., Serrano-Pozo, A., Shelanski, M. L., Stein, T., Takao, M., Thal, D. R., Toledo, J. B., Troncoso, J. C., Vonsattel, J. P., White, C. L., Wisniewski, T., Woltjer, R. L., Yamada, M., & Nelson, P. T.
- Affiliations
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- Rush University Medical Center (US)
- University of Kentucky (US)
- Uppsala University (SE)
- Newcastle University (GB)
- Banner Sun Health Research Institute (US)
- Northwestern University (US)
- Washington University in St. Louis (US)
- Mayo Clinic (US)
- Emory University (US)
- Universidade de São Paulo (BR)
- Icahn School of Medicine at Mount Sinai (US)
- Harvard University (US)
- University of Pittsburgh Medical Center (US)
- University of Washington (US)
- University of British Columbia (CA)
- University of California San Diego (US)
- Boston University (US)
- University of California, San Francisco (US)
- Tokyo Metropolitan Geriatric Hospital (JP)
- Universität Ulm (DE)
- The University of Texas Southwestern Medical Center (US)
- Oregon Health & Science University (US)
- Kanazawa University (JP)
- Corresponding author
- Crary, John F.
- Nelson, Peter T.
- ORCID
- Crary, John F.
- Trojanowski, John Q.
- Schneider, Julie A.
- Abisambra, Jose F.
- Abner, Erin L.
- Alafuzoff, Irina
- Arnold, Steven E.
- Attems, Johannes
- Beach, Thomas G.
- Bigio, Eileen H.
- Dickson, Dennis W.
- Gearing, Marla
- Grinberg, Lea T.
- Hof, Patrick R.
- Hyman, Bradley T.
- Jellinger, Kurt
- Jicha, Gregory A.
- Knopman, David S.
- Kofler, Julia
- Kukull, Walter A.
- Mackenzie, Ian R.
- Masliah, Eliezer
- McKee, Ann
- Montine, Thomas J.
- Murray, Melissa E.
- Neltner, Janna H.
- Seeley, William W.
- Shelanski, Michael L.
- Stein, Thor
- Takao, Masaki
- Thal, Dietmar R.
- Troncoso, Juan C.
- White, Charles L.
- Woltjer, Randall L.
- Yamada, Masahito
- Nelson, Peter T.
- Venue
- Acta Neuropathologica
- Published
- 2014-10-28
- Volume
- 128
- Issue
- 6
- Pages
- 755-766
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4257842
- OpenAlex
- W1971032265
- Cited by
- 1,467
- References
- 160
- Citations by year
- 2026: 85 · 2025: 126 · 2024: 154 · 2023: 123 · 2022: 154 · 2021: 142 · 2020: 143 · 2019: 131 · 2018: 107 · 2017: 119 · 2016: 105 · 2015: 68 · 2014: 9
- FWCI
- 66.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Association (P30 AG013854, P30AG010124, P01 AG003991, P50 AG025688, P50 AG005681, NIRG-11-204450, P50 AG005136, P50 AG005146)
- BrightFocus Foundation (U01 AG006786, P50 AG016574, P50 AG005136)
- Mayo Foundation for Medical Education and Research (AG016574)
- Alzheimer Forschung Initiative (#13803)
- Alzheimer's Society (AS-PG-2013-011)
- National Institute for Health and Care Research
- Bundesministerium für Bildung und Forschung
- National Institutes of Health (AG028 383, 5r01ag038651-10, AG016574, AG010124, AG005138, AG005133, AG005131, AG008051, AG005681, AG019610, AG003991, AG013854, AG025688, AG003949, AG005136, AG011378)
- Medical Research Council (G0400074, U01 AG006786)
- Japan Society for the Promotion of Science (26430060)
- National Institute on Aging (AG008051, R01‐AG038651, R01AG037212, P30AG028383, P01AG007232, P30AG012300, R37AG018440, P50AG005133, AG184440, U01AG016976, P50AG005131, P50AG005138, U01AG006786, P01AG003949, P30AG010124, AG005131, R01AG011378, P30AG008051, P50AG008702, P50AG005681, P30AG036453, P30AG019610, P50AG005146, P01AG003991, P30AG013846, P50AG005136, P30AG013854, P50AG025688, R01AG041851, P01AG002219, P01AG019724, P50AG016574)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- primary age-related tauopathy, neurofibrillary tangles, tau pathology, Alzheimer's disease, nomenclature, temporal lobe atrophy, tau biomarkers, tau imaging, brain aging, cognitive impairment
- MeSH terms
- Aging, Brain, Diagnosis, Differential, Humans, Terminology as Topic, Tauopathies, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
